Scalper1 News
Big-cap biotech Celgene (CELG) reported Wednesday that its drug Otezla failed a trial for an inflammatory spinal disease, but the stock rebounded from an early drop as analysts said the news wasn’t a surprise. The phase three study looked at Otezla for ankylosing spondylitis, an immunological disease that causes pain and sometimes fusion in the spinal cord. There was not a statistically significant improvement overall in patients taking Otezla vs. Scalper1 News
Scalper1 News